Enliven therapeutics, inc.ELVN.US Overview
US StockHealthcare
(No presentation for ELVN)
ELVN Overall Performance
ELVN AI Analysis & Strategy
ELVN Recent Performance
4.83%
Enliven therapeutics, inc.
0.81%
Avg of Sector
-1.14%
S&P500
ELVN PowerScanner
ELVN Key Information
ELVN Valuation Metrics
ELVN Earnings Table
ELVN Profile
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.